Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice

Thais Garcias Moreira, Ana Cristina Gomes-Santos, Laila Sampaio Horta, Mariana Camila Goncalves, Andrezza Fernanda Santiago, Juliana Gonçalves Lauar, Daniela Silva dos Reis, Archimedes Barbosa Castro-Junior, Luisa Lemos, Mauro Guimarães, Edenil Costa Aguilar, Attila Pap, Joana Ferreira Amaral, Jacqueline I. Alvarez-Leite, Denise Carmona Cara, Rafael Machado Rezende, L. Nagy, Ana Maria Caetano Faria, Tatiani Uceli Maioli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dietary supplementation with conjugated linoleic acid (CLA) has been proposed for weight management and to prevent gut inflammation. However, some animal studies suggest that supplementation with CLA leads to the development of nonalcoholic fatty liver disease. The aims of this study were to test the efficiency of CLA in preventing dextran sulfate sodium (DSS)-induced colitis, to analyze the effects of CLA in the liver function, and to access putative liver alterations upon CLA supplementation during colitis. So, C57BL/6 mice were supplemented for 3 weeks with either control diet (AIN-G) or 1% CLA-supplemented diet. CLA content in the diet and in the liver of mice fed CLA containing diet were accessed by gas chromatography. On the first day of the third week of dietary treatment, mice received ad libitum a 1.5%–2.5% DSS solution for 7 days. Disease activity index score was evaluated; colon and liver samples were stained by hematoxylin and eosin for histopathology analysis and lamina propria cells were extracted to access the profile of innate cell infiltrate. Metabolic alterations before and after colitis induction were accessed by an open calorimetric circuit. Serum glucose, cholesterol, triglycerides and alanine aminotransaminase were measured; the content of fat in liver and feces was also accessed. CLA prevented weight loss, histopathologic and macroscopic signs of colitis, and inflammatory infiltration. Mice fed CLA-supplemented without colitis induction diet developed steatosis, which was prevented in mice with colitis probably due to the higher lipid consumption as energy during gut inflammation. This result suggests that CLA is safe for use during gut inflammation but not at steady-state conditions.

Original languageEnglish
Pages (from-to)238-245
Number of pages8
JournalJournal of Nutritional Biochemistry
Volume57
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Conjugated Linoleic Acids
Colitis
Nutrition
Diet
Inflammation
Liver
Dextran Sulfate
Hematoxylin
Eosine Yellowish-(YS)
Dietary Supplements
Inbred C57BL Mouse
Infiltration
Feces
Alanine
Gas chromatography
Gas Chromatography
Weight Loss
Colon
Mucous Membrane
Animals

Keywords

  • Colitis
  • Conjugated Linoleic Acid
  • DSS
  • Inflammation
  • Metabolism
  • Steatosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Nutrition and Dietetics
  • Clinical Biochemistry

Cite this

Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice. / Moreira, Thais Garcias; Gomes-Santos, Ana Cristina; Horta, Laila Sampaio; Goncalves, Mariana Camila; Santiago, Andrezza Fernanda; Lauar, Juliana Gonçalves; dos Reis, Daniela Silva; Castro-Junior, Archimedes Barbosa; Lemos, Luisa; Guimarães, Mauro; Aguilar, Edenil Costa; Pap, Attila; Amaral, Joana Ferreira; Alvarez-Leite, Jacqueline I.; Cara, Denise Carmona; Rezende, Rafael Machado; Nagy, L.; Faria, Ana Maria Caetano; Maioli, Tatiani Uceli.

In: Journal of Nutritional Biochemistry, Vol. 57, 01.07.2018, p. 238-245.

Research output: Contribution to journalArticle

Moreira, TG, Gomes-Santos, AC, Horta, LS, Goncalves, MC, Santiago, AF, Lauar, JG, dos Reis, DS, Castro-Junior, AB, Lemos, L, Guimarães, M, Aguilar, EC, Pap, A, Amaral, JF, Alvarez-Leite, JI, Cara, DC, Rezende, RM, Nagy, L, Faria, AMC & Maioli, TU 2018, 'Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice', Journal of Nutritional Biochemistry, vol. 57, pp. 238-245. https://doi.org/10.1016/j.jnutbio.2018.04.003
Moreira, Thais Garcias ; Gomes-Santos, Ana Cristina ; Horta, Laila Sampaio ; Goncalves, Mariana Camila ; Santiago, Andrezza Fernanda ; Lauar, Juliana Gonçalves ; dos Reis, Daniela Silva ; Castro-Junior, Archimedes Barbosa ; Lemos, Luisa ; Guimarães, Mauro ; Aguilar, Edenil Costa ; Pap, Attila ; Amaral, Joana Ferreira ; Alvarez-Leite, Jacqueline I. ; Cara, Denise Carmona ; Rezende, Rafael Machado ; Nagy, L. ; Faria, Ana Maria Caetano ; Maioli, Tatiani Uceli. / Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice. In: Journal of Nutritional Biochemistry. 2018 ; Vol. 57. pp. 238-245.
@article{8eb158e5fe134536bc7997e6bead9d1e,
title = "Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice",
abstract = "Dietary supplementation with conjugated linoleic acid (CLA) has been proposed for weight management and to prevent gut inflammation. However, some animal studies suggest that supplementation with CLA leads to the development of nonalcoholic fatty liver disease. The aims of this study were to test the efficiency of CLA in preventing dextran sulfate sodium (DSS)-induced colitis, to analyze the effects of CLA in the liver function, and to access putative liver alterations upon CLA supplementation during colitis. So, C57BL/6 mice were supplemented for 3 weeks with either control diet (AIN-G) or 1{\%} CLA-supplemented diet. CLA content in the diet and in the liver of mice fed CLA containing diet were accessed by gas chromatography. On the first day of the third week of dietary treatment, mice received ad libitum a 1.5{\%}–2.5{\%} DSS solution for 7 days. Disease activity index score was evaluated; colon and liver samples were stained by hematoxylin and eosin for histopathology analysis and lamina propria cells were extracted to access the profile of innate cell infiltrate. Metabolic alterations before and after colitis induction were accessed by an open calorimetric circuit. Serum glucose, cholesterol, triglycerides and alanine aminotransaminase were measured; the content of fat in liver and feces was also accessed. CLA prevented weight loss, histopathologic and macroscopic signs of colitis, and inflammatory infiltration. Mice fed CLA-supplemented without colitis induction diet developed steatosis, which was prevented in mice with colitis probably due to the higher lipid consumption as energy during gut inflammation. This result suggests that CLA is safe for use during gut inflammation but not at steady-state conditions.",
keywords = "Colitis, Conjugated Linoleic Acid, DSS, Inflammation, Metabolism, Steatosis",
author = "Moreira, {Thais Garcias} and Gomes-Santos, {Ana Cristina} and Horta, {Laila Sampaio} and Goncalves, {Mariana Camila} and Santiago, {Andrezza Fernanda} and Lauar, {Juliana Gon{\cc}alves} and {dos Reis}, {Daniela Silva} and Castro-Junior, {Archimedes Barbosa} and Luisa Lemos and Mauro Guimar{\~a}es and Aguilar, {Edenil Costa} and Attila Pap and Amaral, {Joana Ferreira} and Alvarez-Leite, {Jacqueline I.} and Cara, {Denise Carmona} and Rezende, {Rafael Machado} and L. Nagy and Faria, {Ana Maria Caetano} and Maioli, {Tatiani Uceli}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.jnutbio.2018.04.003",
language = "English",
volume = "57",
pages = "238--245",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice

AU - Moreira, Thais Garcias

AU - Gomes-Santos, Ana Cristina

AU - Horta, Laila Sampaio

AU - Goncalves, Mariana Camila

AU - Santiago, Andrezza Fernanda

AU - Lauar, Juliana Gonçalves

AU - dos Reis, Daniela Silva

AU - Castro-Junior, Archimedes Barbosa

AU - Lemos, Luisa

AU - Guimarães, Mauro

AU - Aguilar, Edenil Costa

AU - Pap, Attila

AU - Amaral, Joana Ferreira

AU - Alvarez-Leite, Jacqueline I.

AU - Cara, Denise Carmona

AU - Rezende, Rafael Machado

AU - Nagy, L.

AU - Faria, Ana Maria Caetano

AU - Maioli, Tatiani Uceli

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Dietary supplementation with conjugated linoleic acid (CLA) has been proposed for weight management and to prevent gut inflammation. However, some animal studies suggest that supplementation with CLA leads to the development of nonalcoholic fatty liver disease. The aims of this study were to test the efficiency of CLA in preventing dextran sulfate sodium (DSS)-induced colitis, to analyze the effects of CLA in the liver function, and to access putative liver alterations upon CLA supplementation during colitis. So, C57BL/6 mice were supplemented for 3 weeks with either control diet (AIN-G) or 1% CLA-supplemented diet. CLA content in the diet and in the liver of mice fed CLA containing diet were accessed by gas chromatography. On the first day of the third week of dietary treatment, mice received ad libitum a 1.5%–2.5% DSS solution for 7 days. Disease activity index score was evaluated; colon and liver samples were stained by hematoxylin and eosin for histopathology analysis and lamina propria cells were extracted to access the profile of innate cell infiltrate. Metabolic alterations before and after colitis induction were accessed by an open calorimetric circuit. Serum glucose, cholesterol, triglycerides and alanine aminotransaminase were measured; the content of fat in liver and feces was also accessed. CLA prevented weight loss, histopathologic and macroscopic signs of colitis, and inflammatory infiltration. Mice fed CLA-supplemented without colitis induction diet developed steatosis, which was prevented in mice with colitis probably due to the higher lipid consumption as energy during gut inflammation. This result suggests that CLA is safe for use during gut inflammation but not at steady-state conditions.

AB - Dietary supplementation with conjugated linoleic acid (CLA) has been proposed for weight management and to prevent gut inflammation. However, some animal studies suggest that supplementation with CLA leads to the development of nonalcoholic fatty liver disease. The aims of this study were to test the efficiency of CLA in preventing dextran sulfate sodium (DSS)-induced colitis, to analyze the effects of CLA in the liver function, and to access putative liver alterations upon CLA supplementation during colitis. So, C57BL/6 mice were supplemented for 3 weeks with either control diet (AIN-G) or 1% CLA-supplemented diet. CLA content in the diet and in the liver of mice fed CLA containing diet were accessed by gas chromatography. On the first day of the third week of dietary treatment, mice received ad libitum a 1.5%–2.5% DSS solution for 7 days. Disease activity index score was evaluated; colon and liver samples were stained by hematoxylin and eosin for histopathology analysis and lamina propria cells were extracted to access the profile of innate cell infiltrate. Metabolic alterations before and after colitis induction were accessed by an open calorimetric circuit. Serum glucose, cholesterol, triglycerides and alanine aminotransaminase were measured; the content of fat in liver and feces was also accessed. CLA prevented weight loss, histopathologic and macroscopic signs of colitis, and inflammatory infiltration. Mice fed CLA-supplemented without colitis induction diet developed steatosis, which was prevented in mice with colitis probably due to the higher lipid consumption as energy during gut inflammation. This result suggests that CLA is safe for use during gut inflammation but not at steady-state conditions.

KW - Colitis

KW - Conjugated Linoleic Acid

KW - DSS

KW - Inflammation

KW - Metabolism

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=85048709505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048709505&partnerID=8YFLogxK

U2 - 10.1016/j.jnutbio.2018.04.003

DO - 10.1016/j.jnutbio.2018.04.003

M3 - Article

AN - SCOPUS:85048709505

VL - 57

SP - 238

EP - 245

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

ER -